Intravacc is partnering with Wageningen Bioveterinary Research and Utrecht University to develop an intranasal COVID-19 vaccine.
Machine learning and artificial intelligence (AI) may resoundingly improve on traditional methods of drug development by biopharmaceutical companies.
Evotec announced that Sanofi will be participating in an organized Public Private Partnership to further the discovery of cutting-edge therapeutic drugs in multiple areas.
Cleara Biotech B.V., a Netherlands-based biopharmaceutical company, announced the creation of three public-private partnerships to discover and develop new therapeutics.
As part of the company’s fourth-quarter 2017 earnings report, Paris-based Sanofi released a pipeline update showing it plans to halt several mid-stage drug programs.
Rhode Island-based MindImmune Therapeutics forged a research agreement with Pfizer to develop treatments for a number of CNS disorders.
Revance Therapeutics Inc. will wait to seek partnerships with bigger drugmakers until the company is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.
Impressive top-line results were reported from a pivotal Phase II study for the PD-1 inhibitor cemiplimab.
Billionaire Mark Cuban invested $250,000 into a small South San Francisco-based biotech company, Perlara, as part of its $7.4 million equity round.
After three years Daiichi Sankyo called it quits regarding the company’s partnership with Charleston Laboratories and took a loss of about $250 million.